Background/Aims: The pro-angiogenic factors vascular endothelial growth factor (VEGF) and angiopoietins (Angs) play a prominent role in synovial angiogenesis, an early and critical event in the pathogenesis of rheumatoid arthritis (RA). Interleukin (IL)-35 is an anti-inflammatory cytokine that attenuates collagen-induced arthritis, however, the mechanisms involved are not fully understood. Methods: The effects of IL-35 on endothelial cell migration, adhesion, and tube formation were examined using human umbilical vein endothelial cells (HUVEC) in vitro. The effects of IL-35 on vessel formation in vivo were examined using a murine Matrigel plugs model. MMP2/MMP9 and IL-6/IL-8 secretion were assessed by zymography and ELISA,
Introduction
Synovial angiogenesis is a critical early event in rheumatoid arthritis (RA), fostering pannus formation, persistent leukocyte infiltration, and lining layer hyperplasia, leading to cartilage and bone destruction [1, 2] . RA angiogenesis is driven and maintained by proangiogenic factors released from RA synovial tissue myeloid cells and fibroblasts, which include vascular endothelial growth factor (VEGF), angiopoietin (Ang)1 and 2, plateletderived growth factor, and transforming growth factor-β [3] [4] [5] . VEGF is the most potent proangiogenic factor in RA angiogenesis, highly expressed in RA [6] , stimulating endothelial cell (EC) proliferation, migration, and vascular tube formation [7] . The EC specific factors Ang1 and Ang2 and their tyrosine kinase receptors Tie1 and Tie2 are also critical in normal and pathological vascular development [8, 9] . Ang1, Ang2, Tie1, and Tie2 are upregulated in RA synovial tissues [10] . Evidence suggests that the Ang/Tie2 signaling pathway mediates the proangiogenic effects of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, and tolllike receptor (TLR)2 in RA [5, 11, 12] . Ang2 neutralization decreases synovial inflammation, neovascularization, and joint destruction in CIA [13] . Higher synovial Tie2 activation in RA patients has prognostic power for the development of erosive disease [14] ; Tie2 blockade inhibits the onset, incidence, and severity of CIA and protects against bone destruction [15] . These findings underscore the significance of this pathway in RA angiogenesis and disease progression.
IL-35 is an anti-inflammatory cytokine of the IL-12 cytokine family that also includes IL-12, IL-23, and IL-27. It is a heterodimer of the IL-27β and IL-12α chains, which are encoded by the Epstein-Barr virus-induced gene 3 (EBI3) and IL12A genes, respectively [16, 17] . IL-35 is primarily produced by regulatory T cells (Tregs) and signals via binding to IL-12Rβ2/ gp130 heterodimers or gp130 and IL-12Rβ2 homodimers, leading to activation of the JAK-STAT pathway [18] . IL-35 supports expansion of CD4 + CD25
+ Tregs, increases their inhibitory function, and induces a new set of Tregs called inducible IL-35-producing Tregs [16, 19, 20] . In contrast to "house-keeping" anti-inflammatory cytokines such as transforming growth factor beta (TGF-β), which are constitutively expressed and inhibit inflammation initiation, IL-35 is induced in response to inflammatory stimuli and suppresses inflammation in full-blown stage [21] . IL-35 curbs the development of various inflammatory syndromes in experimental models [16, [22] [23] [24] . In particular, IL-35 effectively attenuates clinical manifestation of CIA, and these anti-CIA effects are accredited to the stimulation of regulatory T cells, suppression of Th17 cells, and induction of IL-10 [22, 23] .
Interestingly, recent studies have shown that IL-35 inhibits LPS-induced EC activation by suppressing the MAPK-AP-1 pathway [25] . Additionally, IL-35 has been reported to stimulate tumorigenesis by promoting tumor angiogenesis [26] . Therefore, we speculated that IL-35 might also play a role in synovial angiogenesis in RA. In this study, we examined the effects of IL-35 on basal and VEGF-induced human umbilical vein endothelial cell (HUVEC) migration and adhesion as well as tube formation in vitro and in vivo. The effects of IL-35 on matrix metalloproteinase and inflammatory cytokine secretion were also examined. The crosstalk between IL-35, VEGF, and Ang2 in HUVECs and RA synovial tissue explants was investigated. Our results revealed that IL-35 inhibited basal and VEGF-induced angiogenesis and inflammation, and these effects were mediated through inhibition of Ang2 expression and disruption of Ang2/Tie2 signal transduction.
Materials and Methods

Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from American Type Culture Collection (ATCC). The cells were cultured in endothelial growth medium from Clonetics (San Diego, CA, USA) under 5% CO 2 , 37°C in a humidified incubator. Cells at early passages (3-7) were grown to 80% confluence and used in the in vitro studies.
Wound healing migration assay HUVEC migration in vitro was measured using the wound healing assay. Briefly, HUVECs were seeded in 60 mm culture dishes and grown to 80% confluence. The medium was replaced with fresh medium containing 20 ng/ml VEGF 165 and various concentrations of IL-35 (0-40 ng/ml). PBS was used as vehicle control for both VEGF 165 and IL-35. Immediately after the medium exchange, a scratch was created with a pipette tip. After 18 h incubation, images (×100 magnification) were captured, and cell migration was quantified by counting the cells that had moved beyond the reference line. In mechanism studies, cells grown to 80% confluence were placed in fresh medium containing 20 ng/ml VEGF 165 , 200 ng/ml Ang2, 40 ng/ml IL-35, and 10 μg/ml anti-Tie2 antibody or anti-IgG control, in combination or alone. A scratch was created and migration was determined after 18 h incubation as above. Each experiment was conducted in triplicate. Human recombinant VEGF 165 (#8065) was purchased from Cell Signaling Technology (Beverly, MA, USA). IL-35 (ALX-522-140-C010) and Ang2 (ENZ-PRT162-0010) were obtained from Enzo Life Sciences (Farmingdale, NY, USA). Anti-Tie2 antibody and anti-IgG control were from R&D systems (Minneapolis, MN, USA).
Chemotactic migration assay
The chemotactic migration of HUVECs was measured using a Transwell chamber with 6,5 mm polycarbonate membranes (8 μm pore size) pre-coated with BD Matrigel™ Basement Membrane Matirx (BD Bioscience, San Jose, CA, USA). HUVECs were incubated in serum free endothelial growth medium without growth factors for 2 h before use. Fresh medium containing 20 ng/ml VEGF 165 was added to the lower chambers. PBS was used as vehicle control for VEGF 165 . HUVECs were trypsinized and suspended in fresh medium containing various concentrations of IL-35 (0-40 ng/ml). The cells were loaded at 2 × 10 4 cells/well to the upper chambers and allowed to migrate for 4 h at 37°C. The cells were subsequently fixed and stained with hematoxylin and eosin. Non-migrating cells on the upper surface of the membrane were removed using a cotton swab. The cells that had migrated to the lower surface of the membrane were counted under a microscopy at ×200 magnification. Cells in eight randomly selected fields of each membrane were counted. Each experiment was conducted in triplicate. In mechanism studies, fresh medium containing 20 ng/ml VEGF 165 and 200 ng/ml Ang2, in combination or alone was added to the lower chambers. Cells suspended in fresh medium containing 40 ng/ml IL-35, 10 μg/ml anti-Tie2, or 10 μg/ml anti-IgG control were loaded to the upper chambers. Chemotactic migration was measured as described above.
Cell adhesion assay
HUVECs (5×10 4 cells/ml) were seeded in fibronectin (FN)-coated 96-well plates. Cells seeded in bovine serum albumin (BSA)-coated plates were used as negative control. After 24 h incubation, cells in FN-coated plates were treated with 20 ng/ml VEGF 165 in the presence of various concentrations of IL-35 (0-40 ng/ml) for 24 h. PBS was used as vehicle control for both VEGF 165 and IL-35. After treatment, cells were washed twice with PBS, and 200 μl of fresh medium containing 5% fetal bovine serum (FBS) and 10% (v/v) MTS reagent were added to the cells. Absorbance at 490 nm was recorded on a microplate reader. Each experiment was conducted in triplicate. In mechanism studies, cells in FN-coated plates were treated for 24 h with 20 ng/ml VEGF 165 , 200 ng/ml Ang2, 40 ng/ml IL-35, and 10 µg/ml anti-Tie2 or anti-IgG control, in combination or alone. After treatment, cell adhesion was determined using the MTS assay as described above.
Tube formation assay HUVEC tube formation was examined as described previously [27] . Briefly, HUVECs (2×10 4 cells/ml) were seeded in Matrigel-coated 96-well plates and incubated with 20 ng/ml VEGF 165 in the presence of various concentrations of IL-35 (0-40 ng/ml) for 18 h. PBS was used as vehicle control for both VEGF 165 and IL-35. After incubation, the formation of capillary-like structures was analyzed by phase contrast microscopy. Each experiment was conducted in triplicate. In mechanism studies, HUVECs seeded in Matrigel-coated plates were incubated for 18 h with 20 ng/ml VEGF 165 , 200 ng/ml Ang2, 40 ng/ml IL-35, and 10 µg/ml antiTie2 or anti-IgG control, in combination or alone. The formation of capillary-like structures was analyzed by phase contrast microscopy. 
Matrigel plug assay
All animal experiments were approved by the Animal Experimentation Ethics Committee of the First Affiliated Hospital of China Medical University (Shenyang, China) and carried out in compliance with the Principles of Laboratory Animal Care (National Society for Medical Research). C57BL/6 mice were obtained from the Animal Experiment Center of Chinese Academy of Sciences (Shanghai, China). Matrigel (500 μl) containing VEGF 165 (500 ng/ml) and heparin (9 U/ml) was subcutaneously injected with or without IL-35 (2 μg) into the abdomen of C57BL/6 mice (4-6 weeks of age). PBS was used as negative control for both VEGF 165 and IL-35. Six mice were included in each treatment group. After 14 days, mice were sacrificed. Matrigel plugs were carefully dissected out. Surrounding connective tissues were removed. Hemoglobin (Hb) levels were measured by the Drabkin method using the Drabkin reagent kit 525 from Sigma (St. Louis, MO, USA). For histological analysis of vascularity, plugs were fixed in 4% formalin, embedded in paraffin, and stained with hematoxylin and eosin.
RA synovial tissue explant culture
To examine Ang2 production by RA synovial tissues, we used an ex vivo RA synovial tissue explant model, which closely mimics the in vivo RA synovial microenvironment [28] . RA synovial tissue explants were collected as surgical waste from individuals undergoing elective RA surgery with informed consent of the patient. The tissues were sectioned into 1 mm cubes, placed in 96-well plates in RPMI 1640 supplemented with streptomycin (100 U/ml) and penicillin (100 U/ml), and subjected to various treatment. PBS was used as negative control for both VEGF 165 and IL-35. Supernatants were harvested for Ang2, IL-6, and IL-8 ELISA and MMP9 and MMP2 gel zymography analyses. All human sample collection procedures were approved by the Ethics Committee of the First Affiliated Hospital of China Medical University (Shenyang, China).
Ang2 ELISA
HUVECs and RA synovial tissue explants in 96-well plates were incubated with VEGF 165 (20 ng/ml) with or without IL-35 (40 ng/ml) for 18 h. PBS was used as negative control for both VEGF 165 and IL-35. The concentrations of Ang2 in the culture supernatants were determined using a human Ang2 Quantikine ELISA Kit from R&D systems (Minneapolis, MN, USA). Absorbance at 450 nm was recorded on a microplate reader.
IL-6 and IL-8 ELISA
RA synovial tissue explants in 96-well plates were incubated with 20 ng/ml VEGF 165 , 200 ng/ml Ang2, and 40 ng/ml IL-35, in combination or alone for 18 h. PBS was used as negative control for VEGF 165 , Ang2, and IL-35. The concentrations of IL-6 and IL-8 in the culture supernatants were determined using human IL-6 [29] and IL-8 Quantikine ELISA Kits from R&D systems, respectively.
MMP-2 and MMP-9 zymography
HUVECs and RA synovial tissue explants in 96-well plates were incubated with 20 ng/ml VEGF 165 , 200 ng/ml Ang2, and 40 ng/ml IL-35, in combination or alone for 18 h. PBS was used as negative control for VEGF 165 , Ang2, and IL-35. The MMP-2 and MMP-9 activities in the culture supernatants were determined by gel zymography as previously described (cite reference of your choice). Briefly, supernatants (10 µl) were separated by 10% SDS-PAGE with 1% gelatin under nonreducing conditions. The gels were washed with 2.5% Triton X-100, incubated with substrate buffer at 37°C for 24 h, and stained with Coomassie blue for 10 min. Gels were visualized using system UVP BioImaging Systems (Upland, CA, USA).
Statistical analysis
All results are expressed as the mean ± SD (standard deviation). Differences between groups were analyzed by the student's t-test or one-way analysis of variance (ANOVA). Statistical analysis was performed using SPSS 17.0 software (SPSS, Chicago, IL, USA). Statistical significance was defined as P< 0.05.
Results
IL-35 inhibits basal and VEGF-enhanced wound healing and chemotactic migration of HUVECs
We used the wound healing and Transwell migration assays to investigate the effects of IL-35 on EC migration in vitro. The results showed that IL-35 significantly inhibited basal
IL-35 inhibits basal and VEGF-enhanced HUVEC adhesion and tube formation
Subsequently, we evaluated the effects of IL-35 on EC adhesion and tube formation in vitro. After 24 h incubation, HUVECs exhibited much stronger adhesion to FN-coated plates compared with BSA-coated plates (Fig. 2A) . IL-35 dose-dependently inhibited basal HUVEC adhesion to FN-coated plates (Fig. 2A) . VEGF 165 at 20 ng/ml significantly enhanced HUVEC adhesion; this pro-adhesive effect of VEGF 165 was significantly reduced by IL-35 in a dose dependent manner (Fig. 2A) . Similarly, IL-35 dose-dependently inhibited both basal and VEGF 165 -enhanced formation of capillary-like structures by HUVECs seeded in Matrigelcoated plates (Fig. 2B) . Therefore, in addition to motility and chemotaxis, IL-35 can directly repress both basal and VEGF-enhanced HUVEC adhesiveness and in vitro angiogenesis.
IL-35 inhibits basal and VEGF-induced angiogenesis in vivo
Finally, we examined the function of IL-35 in angiogenesis in vivo using the murine Matrigel plug model. In this assay, test compounds are loaded into liquid Matrigel which, after subcutaneous injection, solidifies and permits penetration by host cells and the formation of new blood vessels [30] . In this study, Matrigel containing VEGF 165 (250 ng) and heparin Wound healing migration assay. HUVECs were incubated with 20 ng/ml VEGF 165 and various concentrations of IL-35 (0-40 ng/ml). PBS was used as vehicle control for both VEGF 165 and IL-35. Cell motility was determined by photography (×100 magnification) 18 h after scratch wounding. (B) Chemotactic migration assay. VEGF 165 (20 ng/ml) was added to the lower Transwell chambers. PBS was used as vehicle control for VEGF 165 . HUVECs suspended in medium containing various concentrations of IL-35 (0-40 ng/ml) were loaded to the upper chambers and allowed to migrate for 4 h. The number of cells that had migrated to the lower surface of the membrane was counted under a microscope (×200 magnification) after hematoxylin and eosin staining. n = 3. *P<0.05, * (Fig. 3A) . VEGF 165 (0.25 μg) injection markedly increased the Hb content; this increase in Hb was significantly diminished by co-injection of IL-35 (2 μg) (Fig. 3A) . In alignment with these changes in Hb content, IL-35 visibly inhibited new blood vessel formation in the plugs under basal and VEGF 165 treatment conditions (Fig. 3B) , demonstrating the anti-angiogenic effects of IL-35 in vivo. 
IL-35 inhibits Ang2, MMP, and cytokine production by HUVEC and RA synovial tissue explants
Previous studies have shown that tumor-derived VEGF drives Ang2 expression in host stroma endothelial cells, and VEGF directly up-regulates Ang2 in cultured endothelial cells via the VEGF receptor-2/flk-1/KDR pathway; thus, the autocrine regulation of Ang2 by VEGF likely plays an important role in the VEGF-Ang cooperation in tumor angiogenesis in vivo [31] . In this study, we found that VEGF 165 at 20 ng/ml significantly increased Ang2 protein secretion by both HUVECs and RA synovial tissue explants after 18 h incubation (Fig 4A) . These results indicated that VEGF likely exerts its proangiogenic effects in RA synovia at least partially through upregulation of Ang2. Interestingly, IL-35 (40 ng/ml) inhibited Ang2 secretion by HUVECs and RA synovial explants under both basal and VEGF treatment conditions (Fig 4A) , suggesting that the anti-angiogenic effects of IL-35 in vitro and in vivo might be mediated through Ang2 downregulation. Moreover, treatment with exogenous VEGF 165 and Ang2, alone or in combination, significantly increased MMP2 and MMP9 activities in the culture supernatants of HUVECs and RA synovial explants (Fig. 4B) . VEGF 165 and Ang2, alone or in combination, also enhanced IL-6 and IL-8 secretion by RA synovial explants (Fig. 4C) . Synergistic effects were observed between these two factors (Fig.  4B, C) . Thus, in addition to its proangiogenic effects, VEGF can contribute to RA synovial inflammation at least partially through upregulation of Ang2. IL-35 decreased MMP2/ MMP9 activities and IL-6/IL-8 concentrations either under basal conditions or with VEGF/ Ang2 treatment, alone or in combination (Fig. 4B, C) , suggesting that IL-35 can suppress RA inflammation through regulation of the VEGF/Ang2 crosstalk. 
IL-35 restrains VEGF-induced HUVEC migration, adhesion, and tube formation via the Ang2/Tie2 pathway
To confirm the involvement of the Ang2/Tie2 pathway in the proangiogenic effects of VEGF, we tested the effects of exogenous Ang2 and a Tie2 kinase antibody (anti-Tie2) that blocks the Ang/Tie2 signaling. Similar to VEGF 165 , Ang2 (200 ng/ml) enhanced HUVEC would healing migration, chemotaxis, adhesion, and tube formation; and synergistic effects were observed between the two factors ( Fig. 5A-D) . Anti-Tie2 (10 μg/ml) inhibited the proangiogenic effects of not only Ang2, but also VEGF 165 (Fig. 5A-D) , confirming that VEGF 165 exerts its proangiogenic effects by increasing the Ang2/Tie2 signaling. Interestingly, the proangiogenic effects of VEGF/Ang2 (alone or in combination) in HUVECs were effectively blocked by IL-35 ( Fig. 5A-D) , suggesting that IL-35 restrains VEGF-induced angiogenesis not only by inhibiting Ang2 expression, but also by suppressing Ang2/Tie2 signal transduction.
Discussion
Persistent angiogenesis supports delivery of nutrients and inflammatory cells to the RA synovia to maintain chronic architectural changes and foster inflammation [32] . Numerous compounds that exhibit anti-rheumatic activities [33] , e.g., interleukins, antibodies against angiogenic factors, and disease-modifying anti-rheumatic drugs, have been found to have anti-angiogenic properties. Emerging evidence implicates that targeting synovial angiogenesis may provide a promising therapeutic approach for RA [34] . Although a broad spectrum of molecules are involved in regulation of angiogenesis, VEGF and Angs, the only known growth factors largely specific for vascular endothelial cells, have been proposed to play a predominant role in neovascularization in RA pathology [35] . In experimental CIA models, VEGF expression is higher in synovial tissues [6, 36] , and correlates with synovial neovascularization and disease severity [37] . Administration of anti-VEGF antiserum before, but not after the onset of the disease delays arthritis progression, suggesting that VEGF plays a critical role in early disease development [37] . Ang2 has been implicated in hypoxia-driven synovial angiogenesis in patients with inflammatory arthritis [38] . Gene therapy against the Ang receptor Tie2 before and after disease onset attenuates severity of arthritis [15] . These findings underscore the potential value of targeting these proangiogenic factors in RA treatment.
Although the cooperation between VEGF and Angs play a critical role in both developmental and pathogenic vascularization, mechanisms regulating the coordinated expression of these molecules remain largely unknown. Studies have shown that VEGF directly upregulates Ang2 in cultured endothelial cells in vitro [31, 39] , and tumor-derived VEGF induces Ang2 expression in host stroma endothelial cells in vivo [31] . In this study, we found that VEGF significantly induced Ang2 expression in HUVECs in vitro and in RA synovial tissue explants ex vivo. Exogenous Ang2 promoted HUVEC migration, adhesion, and tube formation with similar potency to VEGF. Blocking the Ang/Tie2 pathway with a Tie2 kinase antibody inhibited the proangiogenic effect of both Ang2 and VEGF in HUVECs. Taken together, these results suggested that VEGF promotes angiogenesis in RA synovial tissues at least partially by upregulating Ang2. This autocrine VEGF/Ang2 crosstalk likely contributes to coordinated actions of these two molecules to drive RA synovial angiogenesis.
In this study, we found that the anti-inflammatory cytokine IL-35 also exhibited strong anti-angiogenic properties. IL-35 significantly decreased both basal and VEGF-induced HUVEC migration and adhesion in vitro as well as tube formation in vitro and in vivo. Our data showed that IL-35 inhibited both basal and VEGF-induced Ang2 expression in HUVECs and in RA synovial tissue explants. Interestingly, IL-35 also antagonized the proangiogenic effects of exogenous Ang2 in HUVECs. These results suggested that IL-35 restrains basal and VEGFinduced angiogenesis by inhibiting Ang2 expression as well as disrupting Ang2/Tie2 signal transduction. Moreover, we found that exogenous VEGF and Ang2 (alone or combination) increased the secretion of MMP2 and MMP9 as well as the inflammatory cytokines IL-6 and IL-8 by HUVECs and RA synovial explants. These results are somewhat in alignment with previous reports that Ang2 promotes inflammatory cytokine production by synovial macrophages [13] . In this study, IL-35 reduced MMP2, MMP9, IL-6, and IL-8 secretion either under basal conditions or with VEGF/Ang2 treatment (alone or in combination), suggesting that IL-35 can curb RA inflammation via regulation of the VEGF/Ang2 crosstalk.
Evidence suggests that the Notch pathway is involved in the proangiogenic effects of VEGF and Ang2 in RA synovial tissues [40] . Meanwhile, the pro-inflammatory effects of Ang2 in RA have been reported to be mediated through NF-κB, MEK/ERK, Akt, JNK, and p38 [13] . IL-35 signaling requires the transcription factors STAT1 and STAT4 [18] . Thus, the IL-35, VEGF, and Ang2 crosstalk involved in RA angiogenesis and inflammation likely engages the interplay of these signaling cascades. In this study, VEGF and Ang2 showed synergetic effects; thus the molecular mechanisms involved in their actions may not be precisely the same. The precise mechanisms involved require further investigation. Previous studies have shown that IL-35 subdues arthritis progression through the stimulation of regulatory T cells, suppression of Th17 cells, and induction of IL-10 [22, 23] . Our findings in this study suggested that IL-35 might delay RA progression by disrupting synovial neovascularization and inflammation through regulation of the VEGF/Ang2 crosstalk. RA angiogenesis and inflammation are controlled by many factors that are in crosstalk with each other. Targeting a single player may not be sufficient to impact disease progression. IL-35 may provide an effective therapy for RA since it antagonizes VEGF and Ang2, the two important driving factors in RA. 
